Search results for "Breast tumor"

showing 10 items of 34 documents

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

2017

Bidirectional cross talk between members of the human epidermal growth factor family of receptors (HER) and the estrogen receptor (ER) is believed to underlie resistance mechanisms that develop in response to treatment with anti-HER agents and endocrine therapy. We investigated the interaction between HER2, HER3 and the ER in vitro using human embryonic kidney cells transfected with human HER2, HER3, and ERα. We also investigated the additive efficacy of combination regimens consisting of anti-HER3 (lumretuzumab), anti-HER2 (pertuzumab), and endocrine (fulvestrant) therapy in vivo. Our data show that both HER2 and HER3 can directly complex with the ER and can mediate phosphorylation of the …

0301 basic medicineCell signalingReceptor ErbB-3Receptor ErbB-2Cancer TreatmentEstrogen receptorlcsh:MedicineSignal transductionBiochemistryMice0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsBreast TumorsMedicine and Health SciencesReceptorlcsh:Scienceskin and connective tissue diseasesMultidisciplinaryRemission InductionEndocrine TherapySignaling cascadesPrecipitation TechniquesTreatment OutcomeReceptors EstrogenOncology030220 oncology & carcinogenesisMonoclonalCell linesFemalePertuzumabBiological culturesmedicine.drugResearch ArticleAdultCell biologyMAPK signaling cascadesPaclitaxelBreast NeoplasmsAntibodies Monoclonal Humanized03 medical and health sciencesBreast cancerCell Line TumorBreast CancermedicineEndocrine systemAnimalsHumansImmunoprecipitationFulvestrantbusiness.industrylcsh:RHEK 293 cellsCancers and NeoplasmsBiology and Life SciencesEstrogensReceptor Cross-TalkLumretuzumabmedicine.diseaseXenograft Model Antitumor AssaysHormonesResearch and analysis methods030104 developmental biologyCancer researchlcsh:QbusinessPloS one
researchProduct

Chemical Composition, In Vitro Antitumor and Pro-Oxidant Activities of Glandora rosmarinifolia (Boraginaceae) Essential Oil

2018

The biological properties of essential oils have been demonstrated in the treatment of several diseases and to enhance the bioavailability of other drugs. In natural habitats the essential oils compounds may play important roles in the protection of the plants as antibacterials, antivirals, antifungals, insecticides and also against herbivores by reducing their appetite for such plants or by repelling undesirable others. We analyzed by gas-chromatography mass spectrometry the chemical composition of the essential oil of aerial parts of Glandora rosmarinifolia (Ten.) D.C. Thomas obtained by hydrodistillation and verified some biological activities on a panel of hepatocellular carcinoma cell …

0301 basic medicineChemical RadicalsAntioxidantmedicine.medical_treatmentMDA-MB-231Cancer Treatmentlcsh:MedicinenaphthoquinoneChemical CompositionBiochemistryPhysical ChemistryditerpeneAntioxidantslaw.invention0302 clinical medicinelawBreast TumorsSUM 149Medicine and Health SciencesBioassaySettore BIO/15 - Biologia FarmaceuticaCytotoxicitylcsh:ScienceMultidisciplinarybiologyTraditional medicineChemistryLiver DiseasesBoraginaceaeBoraginaceaeOxidantsHep3BLipidsChemistryOncology030220 oncology & carcinogenesisPhysical SciencesResearch ArticleHepG2Free RadicalsCell SurvivalGastroenterology and HepatologyCarcinomas03 medical and health sciencesInhibitory Concentration 50Cell Line TumorAromatic HydrocarbonsGastrointestinal TumorsBreast CancermedicineOils VolatileHumansPlant OilsEssential oilcytotoxic activityHA22T/VGH; HepG2; Hep3B; SUM 149; MDA-MB-231; cytotoxic activity; diterpenes; naphthoquinones; plant secondary metabolitesVolatile Organic CompoundsDose-Response Relationship DrugCell growthPlant ExtractsHA22T/VGHlcsh:RChemical CompoundsBiology and Life SciencesCancers and NeoplasmsEpithelial CellsHepatocellular CarcinomaSettore CHIM/06 - Chimica OrganicaPlant Components Aerialbiology.organism_classificationPro-oxidantplant secondary metabolitesAntineoplastic Agents PhytogenicHydrocarbonsBioavailability030104 developmental biologySettore BIO/03 - Botanica Ambientale E ApplicataHepatocytesSettore BIO/14 - Farmacologialcsh:QOils
researchProduct

Integrative analysis of structural variations using short-reads and linked-reads yields highly specific and sensitive predictions.

2020

Genetic diseases are driven by aberrations of the human genome. Identification of such aberrations including structural variations (SVs) is key to our understanding. Conventional short-reads whole genome sequencing (cWGS) can identify SVs to base-pair resolution, but utilizes only short-range information and suffers from high false discovery rate (FDR). Linked-reads sequencing (10XWGS) utilizes long-range information by linkage of short-reads originating from the same large DNA molecule. This can mitigate alignment-based artefacts especially in repetitive regions and should enable better prediction of SVs. However, an unbiased evaluation of this technology is not available. In this study, w…

0301 basic medicineFalse discovery rateComputer scienceArtificial Gene Amplification and ExtensionPolymerase Chain ReactionDatabase and Informatics MethodsSequencing techniques0302 clinical medicineBreast TumorsBasic Cancer ResearchMedicine and Health SciencesDNA sequencingBiology (General)EcologyHigh-Throughput Nucleotide SequencingGenomicsDNA Neoplasm3. Good healthIdentification (information)OncologyComputational Theory and MathematicsModeling and SimulationMCF-7 CellsFemaleSequence AnalysisResearch ArticleBioinformaticsQH301-705.5Breast NeoplasmsGenomicsComputational biologyResearch and Analysis MethodsHuman Genomics03 medical and health sciencesCellular and Molecular NeuroscienceCancer GenomicsGenomic MedicineBreast CancerGeneticsDNA Barcoding TaxonomicHumansMolecular Biology TechniquesMolecular BiologyEcology Evolution Behavior and SystematicsWhole genome sequencingLinkage (software)Whole Genome SequencingGenome HumanDideoxy DNA sequencingGenetic Diseases InbornCancers and NeoplasmsBiology and Life SciencesComputational BiologyStatistical modelSequence Analysis DNARepetitive RegionsLogistic Models030104 developmental biologyGenomic Structural VariationHuman genomeSequence Alignment030217 neurology & neurosurgeryPLoS Computational Biology
researchProduct

Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response

2020

Metformin, a biguanide agent, is the first-line treatment for type 2 diabetes mellitus due to its glucose-lowering effect. Despite its wide application in the treatment of multiple health conditions, the glycemic response to metformin is highly variable, emphasizing the need for reliable biomarkers. We chose the RNA-Seq-based comparative transcriptomics approach to evaluate the systemic effect of metformin and highlight potential predictive biomarkers of metformin response in drug-naive volunteers with type 2 diabetes in vivo. The longitudinal blood-derived transcriptome analysis revealed metformin-induced differential expression of novel and previously described genes involved in cholester…

0301 basic medicineMaleendocrine system diseasesMolecular biologyGene ExpressionType 2 diabetesPharmacologyBiochemistryTranscriptome0302 clinical medicineEndocrinologyMedical ConditionsSequencing techniquesGastrointestinal CancersBreast TumorsMedicine and Health SciencesHomeostasisEnergy-Producing OrganellesWhole bloodMultidisciplinarySmall nuclear RNABiguanideQRRNA sequencingGenomicsMiddle AgedMetforminMetforminMitochondriaType 2 DiabetesNucleic acidsCholesterolSmall nucleolar RNAOncology030220 oncology & carcinogenesisMedicineFemaleCellular Structures and OrganellesTranscriptome Analysismedicine.drugResearch Articlemedicine.drug_classEndocrine DisordersScienceGastroenterology and HepatologyBioenergetics03 medical and health sciencesBreast CancermedicineGeneticsDiabetes MellitusHumansNon-coding RNAGlycemicAgedbusiness.industryGene Expression ProfilingType 2 Diabetes Mellitusnutritional and metabolic diseasesBiology and Life SciencesComputational BiologyCancers and NeoplasmsCell Biologymedicine.diseaseGenome AnalysisGene regulationGene expression profilingResearch and analysis methods030104 developmental biologyMolecular biology techniquesMetabolic DisordersRNAbusinessBlood Chemical AnalysisPLoS ONE
researchProduct

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

2019

BackgroundEribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy.MethodsPatients with primary triple negative breast cancer ≥2 cm received doxorubicin 60 mg/m2 and paclitaxel 200 mg/m2 x 4 cycles (AT) followed by E 1.4 mg/m2 x 4 cycles. Primary endpoint was pathological complete response (pCR) rate; secondary and explorative endpoints included clinical/metabolic response rates and safety, and biomarker analysis, respectively. Using a two-stage Simon design, 43 patients were to be included provided that 4 of 13 patients had achieved pCR in the…

0301 basic medicineOncologyCancer TreatmentTriple Negative Breast NeoplasmsImmunostainingToxicologyPathology and Laboratory MedicineBiochemistryMetastasis0302 clinical medicineBreast TumorsClinical endpointMedicine and Health Sciencesmetastatic breast cancer Eribulin mesylate epithelial–mesenchymal transition.AnthracyclinesTriple-negative breast cancerStainingMultidisciplinaryPharmaceuticsQRKetonesMetastatic breast cancerNeoadjuvant TherapyTreatment OutcomeSurgical OncologyOncology030220 oncology & carcinogenesisMedicineFemaleTaxoidsResearch ArticleAdultBridged-Ring CompoundsClinical Oncologymedicine.medical_specialtyAnthracyclineScienceSurgical and Invasive Medical ProceduresNeutropeniaResearch and Analysis Methods03 medical and health sciencesCancer ChemotherapyBreast cancerbreast cancerDrug TherapyInternal medicinemedicineHumansChemotherapyFuransTaxaneToxicitybusiness.industryCancers and NeoplasmsBiology and Life Sciencesmedicine.disease030104 developmental biologySpecimen Preparation and TreatmentMED/06 - ONCOLOGIA MEDICAClinical MedicinebusinessBiomarkers
researchProduct

Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.

2019

BackgroundIn this study based on the BRENDA data, we investigated the impact of endocrine ± chemotherapy for luminal A, nodal positive breast cancer on recurrence free (RFS) and overall survival (OS). In addition, we analysed if tumor size of luminal A breast cancer influences survival in patients with the same number of positive lymph nodes.MethodsIn this retrospective multi-centre cohort study data of 1376 nodal-positive patients with primary diagnosis of luminal A breast cancer during 2001-2008 were analysed. The results were stratified by therapy and adjusted by age, tumor size and number of affected lymph nodes.ResultsIn our study population, patients had a good to excellent prognosis …

0301 basic medicineOncologyDose-dense chemotherapyAdjuvant Chemotherapymedicine.medical_treatmentCancer Treatment0302 clinical medicineBreast TumorsMedicine and Health SciencesEndocrine TumorsMultidisciplinaryPharmaceuticsQREndocrine TherapyMiddle AgedPrognosisSurvival RateOncologyDocetaxelChemotherapy AdjuvantLymphatic Metastasis030220 oncology & carcinogenesisMedicineFemaleLymphAnatomyResearch Articlemedicine.drugClinical Oncologymedicine.medical_specialtyScienceBreast NeoplasmsDisease-Free SurvivalLymphatic SystemCancer Chemotherapy03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancermedicineHumansChemotherapyEndocrine systemSurvival rateAgedRetrospective StudiesChemotherapybusiness.industryBiology and Life SciencesCancers and NeoplasmsRetrospective cohort studymedicine.disease030104 developmental biologyLymph NodesClinical MedicinebusinessPLoS ONE
researchProduct

Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study

2017

Context The molecular subtype of breast tumours plays a major role in cancer prognosis and treatment options. Triple negative tumours (TN) carry the worst prognosis and affects most frequently women of low socioeconomic status (SES). Studies have shown that non-biologic factors, such as the socioeconomic status could have an influence on tumour biology. To this date no study has been done investigating this association in French women. The objective is to study the association between the SES and the molecular tumour subtype of breast cancer patients in the French county of Cote d’Or. This study benefits from the population data from the Cote d’Or breast cancer registry known for its strict…

0301 basic medicineOncologyMultivariate analysisReceptor ErbB-2Social Scienceslcsh:MedicineBiochemistryGeographical Locations0302 clinical medicineSociologyBreast TumorsMedicine and Health SciencesEthnicitiesMedicineFrench PeopleRegistrieslcsh:ScienceLymph nodeMultidisciplinaryMiddle AgedEuropemedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemaleFranceResearch ArticleAdultmedicine.medical_specialtyBreast NeoplasmsContext (language use)03 medical and health sciencesBreast cancerDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosisHumansSocial StratificationSocioeconomic statusGynecologybusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesCancermedicine.diseaseHormonesPopulation based studyClinical trial030104 developmental biologyMetastatic TumorsSocioeconomic FactorsPeople and PlacesPopulation Groupingslcsh:QbusinessPLOS ONE
researchProduct

Systemic Treatment in Advanced Phyllodes Tumor of the Breast: A Multi-institutional European Retrospective Case-series Analyses

2022

Abstract Background: We aimed at investigating outcome of systemic treatments in advanced breast PT. Methods: All cases of advanced breast PT treated with systemic treatments from 1999 to 2019, in one of the referral sarcoma centres involved in the study, were retrospectively reviewed. Results: 56 female patients were identified. Median age was 52 (range 25-76) years. Patients re-ceived a median number of 2 systemic treatments (range 1-4). Best responses according to RECIST were: 1 (3.7%) CR, 11 (40.7%) PR, 6 (22.2%) SD, 9 (33.3%) PD with anthracyclines plus ifosfamide (AI); 2 (16.7%) PR, 4 (33.3%) SD, 6 (50.0%) PD with anthracycline alone; 3 (18.8%) PR, 4 (25.0%) SD, 9 (56.3%) PD with high…

AdultOncologyCancer Researchmedicine.medical_specialtyAdvanced setting; Breast tumor; Chemotherapy; Phyllodes; SarcomaBreast tumorBreast NeoplasmsAdvanced settingInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineChemotherapyResponse Evaluation Criteria in Solid TumorsAgedRetrospective StudiesSeries (stratigraphy)business.industryPhyllodes tumorPhyllodesSarcomaMiddle Agedmedicine.diseaseOncologyFemalebusiness
researchProduct

Validity of the study of sentinel lymph nodes in the treatment of breast carcinoma.

2004

Since it was introduced in the 1990s, axillary sentinel lymph-node biopsy has been rapidly and widely adopted to avoid complete axillary dissection (though this is still the standard procedure). The aims of the study were two-fold: (i) to determine the value of different techniques of sentinel lymph-node identification and (ii) to verify the predictive value of such procedures through histological examination of the sentinel lymph node and axillary dissection in the same patients. Both sentinel lymph-node biopsy and axillary dissection were performed in 230 patients with T1 and T2 (< 3 cm) carcinoma of the breast. Preoperative lymphoscintigraphy was able to identify the sentinel lymph node …

Adultbreast tumorSentinel Lymph Node BiopsyCarcinomaarticleReproducibility of ResultsReproducibility of ResultBreast NeoplasmsPredictive Value of Testprediction and forecastingMiddle AgedEMTREE medical terms: adultvalidation study MeSH: AdultagedProspective StudiefemalePredictive Value of TestsHumanspathologyProspective StudieshumanreproducibilityBreast Neoplasmprospective study
researchProduct

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

2011

Background\ud Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating osteoclasts formation and activity. RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG.\ud \ud Materials and Methods\ud We examined mRNA expression levels of RANKL/RANK/OPG in a publicly available microarray dataset of 295 primary breast cancer patients. We next analyzed RANK expression by immunohistochemistry in an independent series of 93 primary breast cancer specimens and investigated a possible association with clinicopathological parameters, bone recurrence and surviv…

Anatomy and PhysiologyMicroarraysSettore MED/06 - Oncologia MedicaCancer TreatmentLigandsMetastasisBone remodelingMetastasisBasic Cancer ResearchBreast TumorsBone and Soft Tissue SarcomasNeoplasm MetastasisMusculoskeletal SystemOligonucleotide Array Sequence AnalysisMultidisciplinaryPredictive markerReceptor Activator of Nuclear Factor-kappa BQRBone metastasisMiddle AgedImmunohistochemistryGene Expression Regulation NeoplasticOncologyRANKLMedicineFemaleResearch Articlemusculoskeletal diseasesmedicine.medical_specialtyHistologyScienceBone NeoplasmsBreast NeoplasmsBiologyBreast cancerAntibody TherapySDG 3 - Good Health and Well-beingOsteoprotegerinInternal medicinemedicineHumansRNA MessengerBoneBiologyAgedBreast cancer bone metastasis RANK-RANKLRANK LigandOsteoprotegerinComputational BiologyCancers and NeoplasmsRANK Ligandmedicine.diseaseEndocrinologyCancer researchbiology.protein
researchProduct